Serologicals has won a US patent for a purification process it has developed that inactivates infectious prions, the defective proteins that cause “mad cow” disease.

The process is part of Serologicals’ bovine-based Ex-Cyte cell culture growth medium.

Serologicals noted that more than half of pharmaceutical drugs utilize bovine-based products.

“(N)o other company can offer a process that actually reduces the mad cow prions while preserving the efficacy of material treated,” said David Dodd, president and CEO of Serologicals. “The issuance of this patent means that with our process we ensure the highest quality of safeguards for our Ex-Cyte product.”